Reversible inhibition of vasoconstriction by thiazolidinediones related to PI3K/Akt inhibition in vascular smooth muscle cells

Biochemical Pharmacology

Volumn 85, Issue 4, 2013, Pages 551-559

  Sinagra, Tiziana ^a   Tamburella, Alessandra ^a   Urso, Vincenzo ^a   Siarkos, Ilias ^a   Drago, Filippo ^a   Bucolo, Claudio ^a   Salomone, Salvatore ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Anti diabetic drugs; Phosphoinositide 3 kinase Akt; PPAR ; Thiazolidinediones; Vascular tone

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; GLITAZONE DERIVATIVE; N(G) NITROARGININE; PHENYLEPHRINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOPROTEIN; PIOGLITAZONE; POTASSIUM CHLORIDE; PROTEIN KINASE B; ROSIGLITAZONE; TROGLITAZONE;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETIC PATIENT; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMORAL ARTERY; IMMUNOBLOTTING; MALE; MYOGRAPHY; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE CONTRACTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; VASOMOTOR REFLEX; VASOSPASM;

ANILIDES; ANIMALS; CHROMANS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMORAL ARTERY; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NITROARGININE; PHOSPHATIDYLINOSITOL 3-KINASES; PPAR GAMMA; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLIDINEDIONES; VASOCONSTRICTION;

EID: 84872675917     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.11.013     Document Type: Article

References (55)

1. G.A. Francis, E. Fayard, F. Picard, and J. Auwerx Nuclear receptors and the control of metabolism Annu Rev Physiol 65 2003 261 311
2. P.B. Watkins, and R.W. Whitcomb Hepatic dysfunction associated with troglitazone N Engl J Med 338 1998 916 917
3. Y. Masubuchi Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review Drug Metab Pharmacokinet 21 2006 347 356
4. S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2007 2457 2471
5. S. Kaul, A.F. Bolger, D. Herrington, R.P. Giugliano, and R.H. Eckel Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation Circulation 121 2010 1868 1877
6. S. Salomone Pleiotropic effects of glitazones: a double edge sword? Front Pharmacol 2 2011 14
7. D. Panigrahy, S. Singer, L.Q. Shen, C.E. Butterfield, D.A. Freedman, and E.J. Chen PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis J Clin Invest 110 2002 923 932
8. C. Jiang, A.T. Ting, and B. Seed PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines Nature 391 1998 82 86
9. M. Ricote, A.C. Li, T.M. Willson, C.J. Kelly, and C.K. Glass The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation Nature 391 1998 79 82
10. S. Sigrist, M. Bedoucha, and U.A. Boelsterli Down-regulation by troglitazone of hepatic tumor necrosis factor-alpha and interleukin-6 mRNA expression in a murine model of non-insulin-dependent diabetes Biochem Pharmacol 60 2000 67 75
11. J. Youssef, and M. Badr Enhanced hepatocarcinogenicity due to agonists of peroxisome proliferator-activated receptors in senescent rats: role of peroxisome proliferation, cell proliferation, and apoptosis Scientific World J 2 2002 1491 1500
12. M. van Bilsen, and F.A. van Nieuwenhoven PPARs as therapeutic targets in cardiovascular disease Expert Opin Ther Targets 14 2010 1029 1045
13. T. Kaur, R.K. Goel, and P. Balakumar Effect of rosiglitazone in sodium arsenite-induced experimental vascular endothelial dysfunction Arch Pharm Res 33 2010 611 618
14. S. Yoshioka, H. Nishino, T. Shiraki, K. Ikeda, H. Koike, and A. Okuno Antihypertensive effects of CS-045 treatment in obese zucker rats Metabolism 42 1993 75 80
15. H. Nomura, H. Yamawaki, M. Mukohda, M. Okada, and Y. Hara Mechanisms underlying pioglitazone-mediated relaxation in isolated blood vessel J Pharmacol Sci 108 2008 258 265
16. I. Siarkos, V. Urso, T. Sinagra, F. Drago, and S. Salomone Endothelium-dependent vasomotor effects of telmisartan in isolated rat femoral arteries Pharmacol Res 63 2011 199 206
17. 2+ currents and increases vascular contractility in a mouse model of type 1 diabetes Br J Pharmacol 161 2010 1458 1471
18. 2+-dependent activation of phosphoinositide 3-kinase class IIalpha isoform-Rho axis in blood vessels of spontaneously hypertensive rats Hypertension 56 2010 934 941
19. D. Carnevale, C. Vecchione, G. Mascio, G. Esposito, G. Cifelli, and K. Martinello PI3Kgamma inhibition reduces blood pressure by a vasorelaxant Akt/L-type calcium channel mechanism Cardiovasc Res 93 2012 200 209
20. 2+-induced, Rho- and Rho kinase-dependent regulation of myosin phosphatase and contraction in isolated vascular smooth muscle cells Mol Pharmacol 71 2007 912 920
21. V. Pomel, J. Klicic, D. Covini, D.D. Church, J.P. Shaw, and K. Roulin Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma J Med Chem 49 2006 3857 3871
22. S. Salomone, E.M. Potts, S. Tyndall, P.C. Ip, J. Chun, and V. Brinkmann Analysis of sphingosine 1-phosphate receptors involved in constriction of isolated cerebral arteries with receptor null mice and pharmacological tools Br J Pharmacol 153 2008 140 147
23. S. Salomone, G. Soydan, M.A. Moskowitz, and J.R. Sims Inhibition of cerebral vasoconstriction by dantrolene and nimodipine Neurocrit Care 10 2009 93 102
24. S. Salomone, G. Soydan, P.C. Ip, K.M. Hopson, and C. Waeber Vessel-specific role of sphingosine kinase 1 in the vasoconstriction of isolated basilar arteries Pharmacol Res 62 2010 465 474
25. M.M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal Biochem 72 1976 248 254
26. T. Miyahara, L. Schrum, R. Rippe, S. Xiong, H.F. Yee Jr., and K. Motomura Peroxisome proliferator-activated receptors and hepatic stellate cell activation J Biol Chem 275 2000 35715 35722
27. S. Han, R.K. Wada, and N. Sidell Differentiation of human neuroblastoma by phenylacetate is mediated by peroxisome proliferator-activated receptor gamma Cancer Res 61 2001 3998 4002
28. D.S. Calnek, L. Mazzella, S. Roser, J. Roman, and C.M. Hart Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells Arterioscler Thromb Vasc Biol 23 2003 52 57
29. S. Goetze, F. Eilers, A. Bungenstock, U. Kintscher, P. Stawowy, and F. Blaschke PPAR activators inhibit endothelial cell migration by targeting Akt Biochem Biophys Res Commun 293 2002 1431 1437
30. L. Zhang, P. Xie, J. Wang, Q. Yang, C. Fang, and S. Zhou Impaired peroxisome proliferator-activated receptor-gamma contributes to phenotypic modulation of vascular smooth muscle cells during hypertension J Biol Chem 285 2010 13666 13677
31. T.F. Franke, D.R. Kaplan, L.C. Cantley, and A. Toker Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate Science 275 1997 665 668
32. S. Salomone, and F. Drago Effects of PPARgamma ligands on vascular tone Curr Mol Pharmacol 5 2012 282 291
33. C. Vecchione, E. Patrucco, G. Marino, L. Barberis, R. Poulet, and A. Aretini Protection from angiotensin II-mediated vasculotoxic and hypertensive response in mice lacking PI3Kgamma J Exp Med 201 2005 1217 1228
34. 2+ channels by phosphatidylinositol 3,4,5-trisphosphate Circ Res 95 2004 300 307
35. P. Viard, A.J. Butcher, G. Halet, A. Davies, B. Nurnberg, and F. Heblich PI3K promotes voltage-dependent calcium channel trafficking to the plasma membrane Nat Neurosci 7 2004 939 946
36. 2+ channel activity by modulating Cavalpha1 protein stability J Cell Biol 184 2009 923 933
37. T. Godfraind, R. Miller, and M. Wibo Calcium antagonism and calcium entry blockade Pharmacol Rev 38 1986 321 416
38. A.P. Somlyo, and A.V. Somlyo Signal transduction and regulation in smooth muscle Nature 372 1994 231 236
39. 2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase Physiol Rev 83 2003 1325 1358
40. T.A. Buchanan, W.P. Meehan, Y.Y. Jeng, D. Yang, T.M. Chan, and J.L. Nadler Blood pressure lowering by pioglitazone. evidence for a direct vascular effect J Clin Invest 96 1995 354 360
41. 2+ currents by PPAR-gamma agonists in cultured hippocampal neurons J Neurochem 109 2009 1800 1811
42. K. Eto, Y. Ohya, Y. Nakamura, I. Abe, and M. Fujishima Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle Eur J Pharmacol 423 2001 1 7
43. A. Rotte, A.F. Mack, M. Bhandaru, D.S. Kempe, N. Beier, and W. Scholz Pioglitazone induced gastric acid secretion Cell Physiol Biochem 24 2009 193 200
44. P.J. Bajwa, J.W. Lee, D.S. Straus, and C. Lytle Activation of PPARgamma by rosiglitazone attenuates intestinal Cl- secretion Am J Physiol Gastrointest Liver Physiol 297 2009 G82 G89
45. S.N. Wu, L.L. Ho, H.F. Li, and H.T. Chiang Regulation of Ca(2+)-activated K+ currents by ciglitazone in rat pituitary GH3 cells J Investig Med 48 2000 259 269
46. K. Shimomura, H. Shimizu, M. Ikeda, S. Okada, M. Kakei, and S. Matsumoto Fenofibrate, troglitazone, and 15-deoxy-Delta12,14-prostaglandin J2 close KATP channels and induce insulin secretion J Pharmacol Exp Ther 310 2004 1273 1280
47. M. Scarsi, M. Podvinec, A. Roth, H. Hug, S. Kersten, and H. Albrecht Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor gamma activity: a combined virtual screening and biological assay approach Mol Pharmacol 71 2007 398 406
48. S. Wakino, K. Hayashi, T. Kanda, S. Tatematsu, K. Homma, and K. Yoshioka Peroxisome proliferator-activated receptor gamma ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase SHP-2 Circ Res 95 2004 e45 e55
49. K.B. Atkins, B. Irey, N. Xiang, and F.C. Brosius 3rd. A rapid, PPAR-gamma-dependent effect of pioglitazone on the phosphorylation of MYPT Am J Physiol Cell Physiol 296 2009 C1151 C1161
50. L. Miao, Y. Dai, and J. Zhang Mechanism of RhoA/Rho kinase activation in endothelin-1-induced contraction in rabbit basilar artery Am J Physiol Heart Circ Physiol 283 2002 H983 H989
51. E.A. Wehrwein, C.A. Northcott, R.D. Loberg, and S.W. Watts Rho/Rho kinase and phosphoinositide 3-kinase are parallel pathways in the development of spontaneous arterial tone in deoxycorticosterone acetate-salt hypertension J Pharmacol Exp Ther 309 2004 1011 1019
52. C.M. Halabi, A.M. Beyer, W.J. de Lange, H.L. Keen, G.L. Baumbach, and F.M. Faraci Interference with PPAR gamma function in smooth muscle causes vascular dysfunction and hypertension Cell Metab 7 2008 215 226
53. N. Begum, O.A. Sandu, M. Ito, S.M. Lohmann, and A. Smolenski Active Rho kinase (ROK-alpha) associates with insulin receptor substrate-1 and inhibits insulin signaling in vascular smooth muscle cells J Biol Chem 277 2002 6214 6222
54. S. Chang, J.A. Hypolite, A. Changolkar, A.J. Wein, S. Chacko, and M.E. DiSanto Increased contractility of diabetic rabbit corpora smooth muscle in response to endothelin is mediated via Rho-kinase beta Int J Impot Res 15 2003 53 62
55. R. Ding, D.Y. Hu, K. Xia, and X.C. Yang Increased RhoA/ROK mRNA expression and function in diabetic vein grafts compared with nondiabetic vein grafts and diabetic arterial grafts Thorac Cardiovasc Surg 58 2010 148 153